Oncology News & Perspectives

Featured Exclusive

For many patients with metastatic urothelial carcinoma, cisplatin-containing chemotherapy is not an option; alternative treatments are greatly needed. Recently, the phase 2 California Cancer Consortium trial, led by Sarmad Sadeghi, MD, PhD, reported that a combined regimen of gemcitabine (Gemzar®, Eli Lilly) and eribulin (Halaven®, Eisai Inc.) demonstrates efficacy in cispl...

Top Oncology Stories

Friday, August 23, 2019
For many patients with metastatic urothelial carcinoma, cisplatin-containing chemotherapy is not an option; alternative treatments are greatly needed. Recently, the phase 2 Cal...
Friday, August 23, 2019
A combination of oral selinexor and dexamethasone shows objective responses in patients with multiple myeloma that is refractory to three different classes of currently availab...
Thursday, August 22, 2019
When oral cancers are discovered in the early stage, the survival rate is 82.8% versus 28% when the disease is found after metastasis; therefore, it is important to implement pr...
Thursday, August 22, 2019
Pancreatic cancer is one of the most aggressive forms of cancer, and owing to limited treatment options, it has one of the lowest survival rates. While patients are commonly...
Wednesday, August 21, 2019
Researchers have identified glioblastoma biomarkers in extracellular vesicles that could enable a liquid biopsy, serving as a more efficient and less invasive means of detec...

Expert Perspectives

For many patients with metastatic urothelial carcinoma, cisplatin-containing chemotherapy is not an option; alternative treatments are greatly needed. Recently, the phase 2 California Cancer Consortium trial, led by Sarmad Sad...
Pancreatic cancer is one of the most aggressive forms of cancer, and owing to limited treatment options, it has one of the lowest survival rates. While patients are commonly treated with radiation therapy, there is a need t...
One of the most common birth defects, congenital heart disease (CHD) is associated with an increased risk of developing cancer. Zacharias Mandalenakis, MD and colleagues conducted a study to further explore the link between...
Abiraterone acetate and enzalutamide are oral androgen signaling inhibitor therapies used in the treatment of patients with advanced prostate cancer. However, because elderly patients with prostate cancer who also have card...
​In the treatment of multiple myeloma, supportive care is essential to mitigating the risks of infection and bone disease. However, a study published recently in Cancer by Smith Giri, MD, MHS, and colleagues found that guideli...

Original Research

Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely rec...
As the number of treatments for recurrent ovarian cancer expands, confusion may develop over which therapeutic strategy is best to use. Numerous patient factors need to be taken into account when deciding on a treatment plan, such...
​In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster pre...
Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-t...
​At the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California, in April 2019, i3 Health surveyed oncology nurses regarding their educational needs on a variety of topics, including immune checkpoint inhibi...

© Copyright 2019 i3 Health. All rights reserved.